JJIM A.I CyberSecurity Scoring
31/03/2026
Access Monitoring Plan
Access Monitoring Plan
No incidents recorded for Johnson & Johnson Innovative Medicine in 2026.
No incidents recorded for Johnson & Johnson Innovative Medicine in 2026.
No incidents recorded for Johnson & Johnson Innovative Medicine in 2026.
Established in 1984, we are a global pharmaceutical company headquartered in Hyderabad, India. Driven by our purpose of ‘Good Health Can’t Wait’, we work to provide access to affordable and innovative medicines. We offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major markets include USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in future growth drivers such as access to novel molecules, digital therapeutics and consumer healthcare. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com. Caution Notice: Dr. Reddy's has been made aware of candidates receiving fraudulent job opportunities from unauthorised recruiting agencies or people impersonating Dr. Reddy's leaders. These fraudulent jobs may be advertised on employment sites or mimic our careers site and company email addresses. Please know that Dr. Reddy's Laboratories has no affiliation or connection to these situations. Dr. Reddy's (and its associated/group companies) follows a formal recruitment process through its own HR department. Please report immediately in case you suspect a fraudulent job. You may raise your concern by: Accessing https://drreddys.ethicspoint.com. Calling on the hotline number. List of hotline numbers are available in https://drreddys.ethicspoint.com. The hotline is available 24x7 in multiple languages. Writing to [email protected] or [email protected]. For our community guidelines on LinkedIn, please visit: https://shorturl.at/LTvNZ
This channel is not intended for U.S. and Canadian visitors. Merck operates in the U.S. and Canada as EMD Serono in Healthcare, MilliporeSigma in Life Science and EMD Electronics in Electronics. An unaffiliated and unrelated company, Merck & Co., Inc., Kenilworth, NJ, US holds the rights in the trademark MERCK in the U.S. and Canada. _______________________________ We are Merck, a leading global science and technology company headquartered in Germany. We are curious explorers, courageous pioneers, and ingenious inventors. Our colleagues across the globe love innovating with science and technology to enrich people’s lives with our solutions in Life Science, Healthcare, and Electronics. Together, we dream big and are passionate about caring for our rich mix of people, customers, patients, and the planet. We believe in the positive power of science and technology. It has determined our actions since 1668 and inspires us to continue researching for a future worth living. As a family-owned company with over 350 years of experience, we stand for sustainability, responsibility, and innovative strength. We take pride in being a diverse and inclusive company that values and fosters the talents and abilities of our employees. That's why we are always looking for curious minds that see themselves imagining the unimaginable with us. Work your Magic and join Merck. Legal Disclaimer: www.merckgroup.com/en/legal-disclaimer.html Data Privacy Declaration: www.merckgroup.com/en/privacy-statement
Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world. A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries. Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases. With a workforce of over 23,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth. People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers. In 2024, Grifols was named one of TIME’s ‘World’s Best Companies’ for the second year in a row, reaffirming our commitment to excellence. We were also recognized by Forbes as one of the "Best Employers for Women 2023," reflecting our dedication to fostering an inclusive and supportive workplace for all. To maintain a positive community and overall respectful communication, please keep our community guidelines in mind.
Parexel is a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, our 24,000+ professionals worldwide work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind — broadening access and making clinical research a care option for anyone, anywhere. Our proven track record spans 40+ years and drives us forward, advancing clinical research in healthcare’s most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Our insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients — With Heart.™ We continue to earn recognition industrywide, including the 2025 Scrip Award for “Best Contract Research Organization – Full-Service Provider,” 2024 Fierce Biotech CRO Award for "Innovative Approaches to Patient-Centric Research" and the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award. Community Guidelines Because Parexel’s social media channels are open to the general public and employees, we are not responsible for views expressed other than our own. However, we do not tolerate posts that are: • Abusive, harassing or threatening to others. • Defamatory, offensive, obscene, vulgar or depicting violence. • Hateful targeting by race/ethnicity, age, color, creed, religion, gender, sexual preference or orientation, nationality or political beliefs. • Sexually explicit or pornographic. • Fraudulent, deceptive, libelous, misleading or unlawful. • Referencing criminal or illegal activity. • Spamming. We reserve the right to remove comments that do not adhere to our guidelines and report users who violate the rules of our page.
The Menarini Group is a leading international pharmaceutical and diagnostics company, present in 140 countries worldwide, with a turnover of 4,37 Billion euro and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic areas, including cardiology, oncology, gastroenterology, pneumology, infectious diseases, diabetes, and anti-inflammatory/analgesics. The Group’s pharmaceutical production is carried out in its 18 manufacturing plants, which produce over 609 million packets of product a year and distribute them to five continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients all over the world. For further information, please visit www.menarini.com For reading our Netiquette, please visit https://www.menarini.com/en-us/data-privacy/netiquette-of-menarini-group For reading our Privacy Notice for social networks users, please visit https://www.menarini.com/en-us/data-privacy/privacy-notice-for-social-network-users-of-menarini-group
Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day. A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology will constitute a future growth driver. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, and Eastern Europe. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, the Group employs over 22,000 people worldwide. -- To report a suspected adverse event with a Servier drug, please visit servier.com
A vertically integrated, Global Pharmaceutical Company. Established in 1989, we are engaged in developing, manufacturing, and marketing a wide range of formulations across several major therapeutic areas including anti-infectives, cardiovascular, anti-diabetic, dermatology, and hormone treatment. We develop, manufacture, and globally distribute a broad range of pharmaceutical products across therapies in multiple dosage forms such as solid orals, liquid orals, topical formulations, injectables (Dry Powder) metered dose inhalers and dry powder inhalers. Our Vision To be a leading global pharmaceutical company by providing high quality, affordable and innovative therapeutic solutions for patients with diverse medical needs. Our Mission To contribute towards improving patients’ quality of life across the globe, by providing effective and accessible medicines.
Lonza is a pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. United by a common purpose, we turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. Founded in Switzerland in 1897, our company is the first and original CDMO, and today we are more dynamic, agile and forward-focused than ever before. As one of the largest Western CDMOs, we bring together a global team of around 18,500 colleagues across five continents to deliver comprehensive, integrated solutions for our customers' complex needs. For our customers and their patients, we bring quality, safety and reliability to bring life-enhancing and life-saving treatments to market at speed and at scale. For our colleagues, we strive to create a sense of belonging and inclusion where every person can thrive and bring their best.
Sandoz is the global leader in generic and biosimilar medicines. Our Purpose is to pioneer access to medicines for patients globally. We are on a mission to drive innovation in the healthcare industry by freeing up resources sustainably and responsibly while continuing to address global health challenges such as antimicrobial resistance. We are present in more than 100 countries and our medicines serve some 500 million people every year. We have two main global businesses: Generics - divided between standard generics and complex generics - and Biosimilars. Read our community engagement guidelines: http://bit.ly/4ofoggc
Latest updates, reports, and threat intel affecting the global network.
Free agent safety C. J. Gardner-Johnson is signing a one-year deal worth up to $6 million with the Buffalo Bills, agents Kevin Conner and...
According to ESPN's Adam Schefter, Chicago Bears free-agent safety CJ Gardner-Johnson has signed a one-year deal with the Buffalo Bills.
Reauthorizing Section 702 of FISA is shaping up to be a major headache for House Speaker Mike Johnson.
Led by Tavari Johnson's 25 points, the Akron Zips defeated the Buffalo Bulls 73-70 in the Mid-American Conference Tournament on Thursday.
Gardner-Johnson appeared in 10 regular season games for Chicago, with two interceptions and 35 tackles...
The Philadelphia Eagles won't be bringing back safety C.J. Gardner-Johnson, who is signing with the Buffalo Bills.
Former Eagles free-agent safety C.J. Gardner-Johnson signed a one-year deal worth up to $6 million with the Bills after finishing the 2025...
As the conflict with Iran continues, Wisconsin U.S. Senators Ron Johnson and Tammy Baldwin are speaking out.
As the conflict with Iran continues, Wisconsin U.S. Senators Ron Johnson and Tammy Baldwin are speaking out.
Graylog is a free and open log management platform. From 6.2.0 until 6.3.12, 7.0.7, and 7.1.2, the DELETE /users/{userId}/tokens/{idOrToken} endpoint implemented by UsersResource.revokeToken() in graylog2-server/src/main/java/org/graylog2/rest/resources/users/UsersResource.java checks USERS_TOKENREMOVE permission against the attacker-controlled userId path parameter before resolving the token selected by idOrToken. An authenticated user can provide an authorized userId while accessTokenService.loadById() or accessTokenService.load() resolves a token belonging to another user, including a service account or administrator, after which accessTokenService.destroy() deletes that token without checking AccessToken.getUserName(). The issue does not expose token contents, but unauthorized deletion causes integrity impact and can disrupt access-token-based integrations. This issue is fixed in versions 6.3.12, 7.0.7, and 7.1.2.
MariaDB Connector/R2DBC is a non-blocking MariaDB and MySQL client implemented in Java. Prior to 1.4.1, org.mariadb:r2dbc-mariadb does not gate clear-text password authentication plugins on transport encryption because the AuthenticationPlugin interface has no capability for a plugin to require a secure connection. A hostile or man-in-the-middle MariaDB server can send an AuthSwitchRequest naming mysql_clear_password or dialog (PAM) over a plain-TCP unencrypted connection, and AuthenticationFlow permits ClearPasswordPluginFlow or PamPluginFlow to return the user's password as cleartext bytes on the wire. The disclosed credentials can subsequently be used to authenticate directly to the database server. This issue is fixed in version 1.4.1.
MariaDB Connector/R2DBC is a non-blocking MariaDB and MySQL client implemented in Java. Prior to 1.4.1, org.mariadb:r2dbc-mariadb encodes and decodes all character data under the assumption that the connection character set is UTF-8. A server can announce a mid-session change to character_set_client through the OK-packet session-state-tracking mechanism, including through SET NAMES executed by a stored routine or trigger, server configuration, or a hostile or man-in-the-middle server. If the new character set is not UTF-8, the driver continues to exchange UTF-8 while the server interprets the same bytes under a different encoding, causing silent data corruption and a client/server charset-confusion mismatch that can defeat byte-wise quoting or escaping. The fix accepts only utf8, utf8mb3, or utf8mb4 after initialization; any other value raises R2dbcNonTransientResourceException with SQLState 08000 and closes the connection. This issue is fixed in version 1.4.1.
MariaDB Connector/J is used to connect applications developed in Java to MariaDB and MySQL databases. Prior to 2.7.14, 3.3.5, 3.4.3, and 3.5.9, the connector encodes and decodes protocol text and performs client-side escaping under the assumption that the connection character set is UTF-8. The server can report a mid-session change to character_set_client through OK-packet session-state tracking, including a change caused by SET NAMES, a stored routine or trigger, server configuration, or a hostile server. If character_set_client changes to a non-UTF-8 value, the driver continues to read and write UTF-8 while the server interprets the same bytes under another encoding, causing silent data corruption and a client/server charset-confusion mismatch that can defeat byte-wise quoting or escaping. The fix accepts only utf8, utf8mb3, or utf8mb4 after initialization; any other value causes SQLException with SQLState 08000 and closes the connection. This issue is fixed in versions 2.7.14, 3.3.5, 3.4.3, and 3.5.9.
MariaDB Connector/J is used to connect applications developed in Java to MariaDB and MySQL databases. Prior to 2.7.14, 3.3.5, 3.4.3, and 3.5.9, PAM dialog authentication can be coerced into transmitting the account password over an insecure connection. The mysql_clear_password plugin is gated behind a secure transport, but the sibling PAM handler SendPamAuthPacketFactory, named dialog by the server, does not declare that requirement and inherits the default secure-required value false; older branches implement the same affected behavior in SendPamAuthPacket. A hostile or man-in-the-middle server can send an Authentication Switch Request for dialog over plain TCP, causing the driver to return the user's password in cleartext when sslMode=DISABLE and restrictedAuth=null, which is the default configuration. Properly verified TLS and local Unix sockets are not exposed to this transport vector. This issue is fixed in versions 2.7.14, 3.3.5, 3.4.3, and 3.5.9.
curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.